Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma

Xavier Leleu, Thomas G. Martin, Hermann Einsele, Roger M. Lyons, Brian G.M. Durie, Karim S. Iskander, Sikander Ailawadhi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Proteasome inhibition is an established treatment strategy for patients with multiple myeloma as proteasome inhibitors (PIs) selectively target and disrupt the protein metabolism of aberrant plasma cells. Since the introduction of the first-in-class PIs bortezomib, the therapeutic landscape for multiple myeloma has shifted with the development of next-generation PIs (carfilzomib and ixazomib) and new classes of agents. Treatment with modern combination therapies has been shown to result in deep responses and improved outcomes, and these potent regimens are increasingly used as frontline therapy. As patients continue to live longer with modern frontline therapy, there will be an increased need for effective regimens after initial treatment failure. Several recent studies have shown that treatment with combination therapy incorporating PIs induces deep and durable responses in patients with relapsed and/or refractory multiple myeloma. In this review, we review pivotal data and discuss the role of PIs-based doublet and triplet regimens for the management of relapsed/refractory multiple myeloma in the era of modern combination therapy.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Proteasome Inhibitors
Multiple Myeloma
Therapeutics
Proteasome Endopeptidase Complex
Plasma Cells
Treatment Failure

Keywords

  • Bortezomib
  • Carfilzomib
  • Efficacy
  • Ixazomib
  • Safety

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. / Leleu, Xavier; Martin, Thomas G.; Einsele, Hermann; Lyons, Roger M.; Durie, Brian G.M.; Iskander, Karim S.; Ailawadhi, Sikander.

In: Clinical Lymphoma, Myeloma and Leukemia, 01.01.2018.

Research output: Contribution to journalArticle

Leleu, Xavier ; Martin, Thomas G. ; Einsele, Hermann ; Lyons, Roger M. ; Durie, Brian G.M. ; Iskander, Karim S. ; Ailawadhi, Sikander. / Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. In: Clinical Lymphoma, Myeloma and Leukemia. 2018.
@article{ad5788430eb34b26a0534b959057d0b2,
title = "Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma",
abstract = "Proteasome inhibition is an established treatment strategy for patients with multiple myeloma as proteasome inhibitors (PIs) selectively target and disrupt the protein metabolism of aberrant plasma cells. Since the introduction of the first-in-class PIs bortezomib, the therapeutic landscape for multiple myeloma has shifted with the development of next-generation PIs (carfilzomib and ixazomib) and new classes of agents. Treatment with modern combination therapies has been shown to result in deep responses and improved outcomes, and these potent regimens are increasingly used as frontline therapy. As patients continue to live longer with modern frontline therapy, there will be an increased need for effective regimens after initial treatment failure. Several recent studies have shown that treatment with combination therapy incorporating PIs induces deep and durable responses in patients with relapsed and/or refractory multiple myeloma. In this review, we review pivotal data and discuss the role of PIs-based doublet and triplet regimens for the management of relapsed/refractory multiple myeloma in the era of modern combination therapy.",
keywords = "Bortezomib, Carfilzomib, Efficacy, Ixazomib, Safety",
author = "Xavier Leleu and Martin, {Thomas G.} and Hermann Einsele and Lyons, {Roger M.} and Durie, {Brian G.M.} and Iskander, {Karim S.} and Sikander Ailawadhi",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clml.2018.08.016",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma

AU - Leleu, Xavier

AU - Martin, Thomas G.

AU - Einsele, Hermann

AU - Lyons, Roger M.

AU - Durie, Brian G.M.

AU - Iskander, Karim S.

AU - Ailawadhi, Sikander

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Proteasome inhibition is an established treatment strategy for patients with multiple myeloma as proteasome inhibitors (PIs) selectively target and disrupt the protein metabolism of aberrant plasma cells. Since the introduction of the first-in-class PIs bortezomib, the therapeutic landscape for multiple myeloma has shifted with the development of next-generation PIs (carfilzomib and ixazomib) and new classes of agents. Treatment with modern combination therapies has been shown to result in deep responses and improved outcomes, and these potent regimens are increasingly used as frontline therapy. As patients continue to live longer with modern frontline therapy, there will be an increased need for effective regimens after initial treatment failure. Several recent studies have shown that treatment with combination therapy incorporating PIs induces deep and durable responses in patients with relapsed and/or refractory multiple myeloma. In this review, we review pivotal data and discuss the role of PIs-based doublet and triplet regimens for the management of relapsed/refractory multiple myeloma in the era of modern combination therapy.

AB - Proteasome inhibition is an established treatment strategy for patients with multiple myeloma as proteasome inhibitors (PIs) selectively target and disrupt the protein metabolism of aberrant plasma cells. Since the introduction of the first-in-class PIs bortezomib, the therapeutic landscape for multiple myeloma has shifted with the development of next-generation PIs (carfilzomib and ixazomib) and new classes of agents. Treatment with modern combination therapies has been shown to result in deep responses and improved outcomes, and these potent regimens are increasingly used as frontline therapy. As patients continue to live longer with modern frontline therapy, there will be an increased need for effective regimens after initial treatment failure. Several recent studies have shown that treatment with combination therapy incorporating PIs induces deep and durable responses in patients with relapsed and/or refractory multiple myeloma. In this review, we review pivotal data and discuss the role of PIs-based doublet and triplet regimens for the management of relapsed/refractory multiple myeloma in the era of modern combination therapy.

KW - Bortezomib

KW - Carfilzomib

KW - Efficacy

KW - Ixazomib

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85054080475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054080475&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2018.08.016

DO - 10.1016/j.clml.2018.08.016

M3 - Article

C2 - 30287200

AN - SCOPUS:85054080475

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -